Research
Overcoming therapeutic resistance in cancer
… limits. Not all cancers are responsive. For lung cancers, despite the fact that ten or so oncogenes (genes which … drug blocks its activity by binding to its active site, but if a secondary mutation occurs which alters this … site, it may prevent binding to the TKI. In another case, described as a “bypass pathway” the appearance of a mutation …Published on: